Edition:
India

Sage Therapeutics advances SAGE-217


Monday, 13 Feb 2017 

Sage Therapeutics Inc - : Sage Therapeutics advances SAGE-217 into placebo-controlled phase 2 clinical trial in major depressive disorder . SAGE-217 was found to be generally well-tolerated with no serious adverse events or discontinuations reported .Statistically significant mean change from baseline was observed by day 2 of study.